BVA-100

BVA-100

A semi-automated device which measures blood volume, providing results in 25–35 minutes with ±2% error.
References in periodicals archive ?
In reporting its mid-year results, Daxor Corporation has seen important developments in 2019, including a 38% rise in kit sales related to the use of its diagnostic device, the BVA-100 Blood Volume Analyzer, in the area of cardiology, an increase from the prior year's growth of 23% in this category.
The study demonstrates that despite the widespread use of formula-derived estimates of plasma volume in heart failure patients, these methods are inaccurate compared to measured volume using the company's BVA-100 blood volume measurement diagnostic.
This technology allows the calculation of Total Body Albumin to be made by the Daxor BVA-100 and extends the capabilities of this device beyond the several volume measures it provides.
DORO, which conducts Daxor's equipment manufacturing, testing and development for the Blood Volume Analyzer BVA-100, will be moving into its new facilities to accommodate its existing operations and planned future research projects.
Among nationally renowned hospitals and other major medical institutions which have purchased the BVA-100 Blood Volume Analyzer after a trial period are the Mayo Clinic, The Cleveland Clinic, NIH, and New York University Medical Center.
CHF Solutions (CHFS) announced that it has entered into a collaboration agreement with Daxor (DXR) to explore potential synergies between the company's Aquadex FlexFlow System and Daxor's BVA-100 Blood Volume Analyzer.
M2 EQUITYBITES-February 9, 2016-Daxor Corporation reports divestiture of BVA-100 Blood Volume Analyzer to Nebraska Medicine
M2 PHARMA-February 9, 2016-Daxor Corporation reports divestiture of BVA-100 Blood Volume Analyzer to Nebraska Medicine
Study author Mark Nelson, MD of Virginia Commonwealth University, stated that the surprising results of his study showed the inadequacy of current methods of evaluating blood loss, including the widespread use of hematocrit and hemoglobin: "Contrary to the long-held belief that red blood cells are largely conserved during cardiac surgery they are in fact reduced by 38%." He added, "This data beckons the question of transfusion, should peripheral hematocrit continue to be utilized as a determinant." CEO COMMENTS ON BVA-100: Michael Feldschuh CEO of Daxor stated, "This study highlights the BVA-100's unique ability to illuminate intravascular fluid derangements that are missed by standard diagnostic tests.
M2 EQUITYBITES-March 16, 2015-Daxor to install its BVA-100 Blood Volume Analyzers in New Jersey and Minnesota
M2 PHARMA-March 16, 2015-Daxor to install its BVA-100 Blood Volume Analyzers in New Jersey and Minnesota
Daxor Corporation exhibited at the 2018 Society for Critical Care Medicine Annual Meeting from February 25-28 in San Antonio, Texas where research was presented highlighting the positive clinical benefits of the use of Daxor's BVA-100 blood volume system for critical care.